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Anti-Phospholipid Antibodies: 

Case Report and Review 

of the Literature 

ABSTRACT 
There is currently considerable interest in 
antibodies directed against phospholipids. 
Several clinical associations with these 
antibodies have been defined, the strongest 
ones being with thrombosis and recurrent 
foetal loss. These antibodies were originally 
studied in patients with systemic lupus 
erythematosus, but they have also been 
found to occur in patients who do not have 
this disease. This paper describes two such 
patients and discusses current views on 
antiphospholipid antibodies 
CASE REPORTS 
Case No. 
The patient, a 22 year old Saudi Arabian 
male, presented with a day's history of 
painful swelling in his left lower limb, which 
was warm and tender. Venography con­
firmed left sided ilio-femoral thrombosis. 
The patient had been well previously, except 
for right sided femoral thrombosis six 
months previously for which he had 
received warfarin for three months. Investig­
ations included: prolonged activated partial 
thromboplastin time (before heparin was 
started), which was not corrected by adding 
normal plasma; normal prothombin time: 
platelet count 60 x 60109/ 1; VDRL positive; 
Treponema pallidum haemagglutination 
test (TPHA) negative; fluorescent anti­
nuclear antibodies negative. IgG anticardio­
lipin antibodies were elevated. The patient 
was anticoagulated, initially with heparin, 
and later with warfarin; aspirin was also 
given in a dose of 300 mg daily. Three years 
after the episode he remains well. 
Case No.2 
A 33 year old of Maltese woman who was in 
the tenth week of her first pregnancy, 
presented with painful swelling of her left 
calf. 
A clinical diagnosis of deep venous throm­
bosis was made, and the patient was 
anticoagulated with heparin for 10 days. 
About 2 months later she developed 
abdominal pain and noted petechiae on her 
lower limbs. Platelet count was 11 x 109/I. 
Abdominal ultrasound showed a dead 20 
week old foetus. Following induction, she 
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passed a dead foetus with an infarcted 
placenta. Investigations showed prolonged 
activitated partial thromboplastin time, 
normal fibrinogen level, absent fibrin 
degradation products, negative VDRL, as 
well as negative fluorescent nuclear and 
anti-double stranded DNA antibodies. Bone 
marrow aspiration showed increase number 
of megakaryocytes. IgG anti-cardiolipin 
antibodies were considerably elevated . The 
patient was treated 'W-ith corticosteroids, the 
initial dose being 60 mg prednisolone daily, 
and one year later she remains well, with 
normal platelet counts and no recurrence of 
deep venous thrombosis. She is on a 
maintenance dose of prednisolone of 10 mg 
daily, and aspirin 300 mg daily. 
COMMENT 
Phospholipids are widely distributed in 
nature. They are found in endothelial cell 
membranes, platelets as well as brain tissue. 
The first antibody to phospholipid that was 
described was reagin, present inthe sera of 
syphilitic patients, and detected by the 
Wasserman reaction. In 1941, it was 
discovered that the antigen bound by reagin 
was a phospholipid that could be extracted 
by alcohol from ox heart muscle: it was 
therefore called cardiolipin. Following 
widespread screeningwith the Wassermann 
test, it soon became clear that some patients 
had a positive test without showing any 
clinical evidence of syphilis. Among this 
group there was a high prevalence of 
autoimmune diseases such as rheumatoid 
arthritis and acquired haemolytic anaemia. 
In 1952 Conley and Hartmann I described 
two patients with systemic lupus erythe­
matosus, both of whom had false positive 
tests for syphilis, as well as prolonged whole 
blood clotting and prothrombin times. The 
clotting defect has since been referred to as 
lupus anticoagulant. There is a close 
correlation between the antibody responsible 
for lupus anticoagulant activity and anti­
cardiolipin, both of which are antiphos­
pholipid antibodies. Anti-cardiolipin anti­
body is also responsible for the false positive 
tests for syphilis. 
Anti-phospholipid antibodies prolong 
phosphoplipid-dependent coagulation tests, 
especially the partial thromboplastin time, 
Russel viper venom time, and - less 
commonly - prothrombin time. It has no 
effect on thrombin time. This prolongation 
is not due to a clotting factor deficiency, 
because the test is not normalised by the 
addition of normal plasma. It is believed 
that the abnormality results from an 
interaction between antiphospholipid anti­
bodies and the phospholipid moiety of the 
prothrombin activator complex, thereby 
interfering with the conversion of proth­
rombin to thrombin (Fig 1). Neither the 
activated partial thromboplastin time nor 
VDRL are sensitive enough to be used as 
screening tests for antiphospholipid anti­
bodies. More sensitive immunoassays are 
now available for their detection". 
Anti-phospholipid antibodies were initially 
studied in patients with connective tissue 
diseases, particularly systemic lupus erythe­
matosus. Various studies quote frequencies 
of these antibodies in 25 to 40% of patients 
with systemic lupus erythematosus.] 4 The 
relationship between anti-phospholipid 
antibodies and antinuclear antibodies is not 
clear. While some studies have shown a 
cross-reaction between anti-DNA antibodies 
and cardiolipin, other have found no such 
correlationS. Some observers believe that 
patients with anti-phospholipid antibodies 
form a separate subgroup of connective 
tissue diseases, the anti-phospholipid anti­
body syndrome, while other feel that such 
patients belong to the same spectrum of 
disease typified by systemic lupus erythe­
matosus. A better understanding of the 
pathogenesis ofthese diseases is required to 
settle the issue. 
Anti-phospholipid antibodies have also 
been identified in patients who have no 
clinical or serological evidence of systemic 
lupus erythematosus or other connective 
tissue disorder" . Several clinical associations 
have been described with these antibodies: 
paradoxically, the strongest one is with 
thrombosis 7 H. Despite the in vitro property 
of these antibodies to prolong coagulation 
tests, 25 - 50'!\, of patients possessing 
antiphospholipid antibodies, whether or not 
suffering from lupus erythematosus, have 
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had thrombotic episodes. No part of the 
vascular bed seems immune from throm­
botic episodes. While thrombosis in the deep 
veins of lower limbs has been most 
commonly described - as in both our 
patients - it also been reported in the renal 
and hepatic veins9, as well as in cerebral, 
coronary, brachial, mesenteric and other 
arteries. Pulmonory hypertension due to 
pulmonary thrombosis in situ or recurrent 
pulmonary embolism has been described l ". 
How these antibodies cause thrombosis is 
uncertain. It has been suggestedG that they 
may interfere with the release of arach­
idonic acid from the endothelial cell 
membrane, thereby reducing prostacyclin 
production. Reduced levels of prostacyclin 
Increase platelet aggregation and thereby 
may facilitate thrombosis. Other altern­
ative explanations have included: 
i) direct platelet activation by binding to 
phospholipid in the platelet membrane; 
ii) reduced plasminogen activator release 
due to immune complex mediated endothe­
lial cell damage; 
iii) inhibitory interaction with a protein C­
phospholipid complex. I I 
There have been several reports of an 
association between anti-cardiolipin anti­
bodies and thrombocytopenia7 12, as was 
noted in both our patients. It is possible that 
the antibodies may bind phospholipids in 
platelet membranes resulting in increased 
uptake and destruction by the reticuloend­
othelial system. Some studies, however, 
have failed to notice such an association l :l 14. 
Another condition associated with these 
antibodies is recurrent abortion. This has 
been noted in patients with systemic lupus 
! 
Fibrinogen~Fibrin 
erythematosus, but it has also been described 
in women who do not have this disease, and 
whose only serological abnormality has 
been the presence of anti-cardiolipin anti­
bodies. In recent clinical studies, anti­
cardiolipin antibodies were present in a 
significant proportion of women with other­
wiseunexplainedrecurrentabortions '511i 17 Pi. 
It has been suggested that reduced prosta­
cyclin production by the placental blood 
vessels may cause platelet aggregation and 
lead to diminished placental blood flow, 
placental infarction and foetal loss. 
Several other associations have been 
described, but less commonly'! 11. These 
include livedo reticularis, various central 
nervous syndromes (cerebral thrombosis, 
transient ischaemic attack, migraine-like 
headaches, epilepsy, chorea, myelopathy) 
as well as positive Coombs test (with and 
without haemolytic anaemia) and labile 
hypertension. 
The management of patients with anti­
phospholipid antibodies is largely empirical, 
as the natural history of the condition has 
not yet been well documented. Although 
there are very few published controlled 
trials, there is evidence that corticosteroids 
and aspirin may produce a successful 
pregnancy outcome in patients with recur­
rent abortion lH 19 . They are also useful in 
managing thrombocytopenia. Anti-coagul­
ants with an antiplatelet agent have been 
recommended for patients in whom vascular 
thrombosis develops; these patients not 
uncommonly relapse once anticoagulant 
therapy is stopped20 - as happened in Case 
No. 1 - and long-term therapy is therefore 
recommended. There is however no current 
evidence to justify prophylactic therapy in 
the hope of lowering antiphospholipid 
antibody levels21 
The clinical associations of antiphos­
pholipid antibodies have expanded consid­
erably over the past few years, and they are 
still a topic of widespread interest. Indeed, 
because of their association, they promise 
implications far beyond the connective 
tissue diseases. However, a cause and effect 
relationship has yet to be proved, and itmay 
eventually be shown that these antibodies 
are of little pathogenic importance. This 
seems unlikely to happen, mainly because of 
the strong clinical associations, particularly 
with thrombosis. As the presence of these 
antibodies may have a bearing on treatment 
and its duration, it is suggested that anti­
phospholipid antibodies should be looked 
for in appropriate clinical settings, such as 
in young patients with thrombosis without 
an obvious cause and in unexplained 
repeated abortions. 
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